NZ589495A - Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant - Google Patents

Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Info

Publication number
NZ589495A
NZ589495A NZ589495A NZ58949509A NZ589495A NZ 589495 A NZ589495 A NZ 589495A NZ 589495 A NZ589495 A NZ 589495A NZ 58949509 A NZ58949509 A NZ 58949509A NZ 589495 A NZ589495 A NZ 589495A
Authority
NZ
New Zealand
Prior art keywords
replicase
seq
expression vector
adjuvant
cells
Prior art date
Application number
NZ589495A
Other languages
English (en)
Inventor
Kaja Kiiver
Rein Sikut
Urve Toots
Tarmo Molder
Andres Mannik
Mart Ustav
Katrin Kaldma
Original Assignee
Fit Biotech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fit Biotech Oy filed Critical Fit Biotech Oy
Publication of NZ589495A publication Critical patent/NZ589495A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ589495A 2008-05-23 2009-05-22 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant NZ589495A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7189808P 2008-05-23 2008-05-23
PCT/EP2009/056240 WO2009141434A1 (en) 2008-05-23 2009-05-22 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Publications (1)

Publication Number Publication Date
NZ589495A true NZ589495A (en) 2012-06-29

Family

ID=40910781

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589495A NZ589495A (en) 2008-05-23 2009-05-22 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant

Country Status (15)

Country Link
US (1) US9474800B2 (enExample)
EP (1) EP2296702A1 (enExample)
JP (1) JP5663474B2 (enExample)
KR (1) KR20110044836A (enExample)
CN (1) CN102083463B (enExample)
AU (1) AU2009248735B2 (enExample)
BR (1) BRPI0913045A2 (enExample)
CA (1) CA2724570A1 (enExample)
IL (1) IL209077A0 (enExample)
MX (1) MX2010012587A (enExample)
NZ (1) NZ589495A (enExample)
RU (1) RU2010152562A (enExample)
SG (1) SG191600A1 (enExample)
WO (1) WO2009141434A1 (enExample)
ZA (1) ZA201007880B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220119D0 (en) * 2012-11-08 2012-12-26 Univ Cork Vector
CN111304201B (zh) * 2020-02-21 2022-10-21 华南农业大学 一种降低乙型脑炎脑病毒感染的siRNA及其应用
AU2021233816A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
BR112023002642A2 (pt) 2020-08-14 2023-04-04 Arcturus Therapeutics Inc Método para liofilizar nanopartículas lipídicas
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用
WO2023133509A2 (en) * 2022-01-08 2023-07-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
KR20240049429A (ko) 2022-10-08 2024-04-16 최주언 황금비율 계량컵

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
JP2002521461A (ja) * 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Ｒｎａウイルスを用いる組換えタンパク質の調節発現
EP1226238A2 (en) * 1999-10-27 2002-07-31 Cytos Biotechnology AG Method for creating divergent populations of nucleic acid molecules and proteins
US7592005B2 (en) * 2000-12-28 2009-09-22 Kirin Beer Kabushiki Kaisha Monoclonal antibody
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
AU2003266301A1 (en) * 2002-08-22 2004-03-11 Cytos Biotechnology Ag Inducible alphaviral/orip based gene expression system
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.
WO2006085983A2 (en) * 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
WO2008085557A2 (en) * 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
HRP20100638T2 (hr) * 2006-11-28 2011-03-31 Proyecto De Biomedicina Cima Viralni vektori i njihova uporaba
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs

Also Published As

Publication number Publication date
AU2009248735A1 (en) 2009-11-26
JP2011523642A (ja) 2011-08-18
CN102083463A (zh) 2011-06-01
RU2010152562A (ru) 2012-06-27
IL209077A0 (en) 2011-01-31
CN102083463B (zh) 2017-04-05
BRPI0913045A2 (pt) 2017-05-23
WO2009141434A1 (en) 2009-11-26
JP5663474B2 (ja) 2015-02-04
EP2296702A1 (en) 2011-03-23
MX2010012587A (es) 2011-05-25
SG191600A1 (en) 2013-07-31
CA2724570A1 (en) 2009-11-26
AU2009248735B2 (en) 2015-08-20
US20110171255A1 (en) 2011-07-14
WO2009141434A4 (en) 2010-01-14
ZA201007880B (en) 2012-02-29
US9474800B2 (en) 2016-10-25
KR20110044836A (ko) 2011-05-02

Similar Documents

Publication Publication Date Title
US10329329B2 (en) Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
CA2526128C (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
AU2009248735B2 (en) Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
US20160215039A1 (en) Agents and methods based on the use of the eda domain of fibronectin
WO2022043449A1 (en) Vaccines based on an antigen protein fused to a nanostructuring scaffold
JP2023528017A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
JP2016520534A (ja) インフルエンザ核タンパク質ワクチン
CN117750974A (zh) 病毒疫苗
US20220184200A1 (en) Virus-like particles and uses thereof
Leng et al. Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA vaccine against bovine viral diarrhea virus in mice
KR102678519B1 (ko) Sting 경로를 활성화하는 유전자 보조제의 발현을 위한 바이러스 벡터 작제물
US20250025548A1 (en) Universal sarbecovirus vaccines
AU2011269729A1 (en) Constrained immunogenic compositions and uses therefor
KR102678544B1 (ko) Cd40 및 sting 경로를 활성화하는 유전자 보조제의 발현을 위한 바이러스 벡터 작제물
US20250213671A1 (en) Novel rna and dna technology for vaccination against alphaviruses and other emerging and epidemic viruses
WO2025106754A1 (en) Coronavirus vaccine
JP2002114708A (ja) Ｄｎａワチンに対するアジュバント剤
Hajam POTENTIATION OF IMMUNE RESPONSE AGAINST FOOT-AND-MOUTH DISEASE VIRUS USING TLR AGONISTS
LAMBDA BARATHIRAJA S
Pollard Evaluation of CD8⁺ T cell responses upon mRNA vaccination and the implication of type I IFN signaling

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 MAY 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130424

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAY 2017 BY VALEA AB

Effective date: 20160517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAY 2018 BY KRISTINA HALLGREN

Effective date: 20170519

LAPS Patent lapsed